Alzheimer’s: Monoclonal antibodies and vaccine candidates effective in mice

Alzheimer’s disease (AD) accounts for 60–70% of all dementia cases and is the sixth Trusted Source leading cause of death in adults in the United States.

Doctors characterize the condition by a progressive decline in cognitive abilities, including memory, reasoning, thinking, and language. Although there are a few drugs that can reduce AD symptoms, there is an absence of treatments, except for the controversial drug aducanumab, which can slow the progression of the disease.

ARTICLE